The Spanish Association of Orphan and Ultra Orphan Drug Laboratories (AELMHU) is part of the Strategic Plan for the Pharmaceutical Industry 2024-2028, which was published yesterday and which recognizes the importance of this sector as a key driver for public health and the economy in Spain. In this way, AELMHU will be part of the stakeholders in the action plan, which is a unique opportunity to actively collaborate with all the actors involved in improving access to treatments for patients with rare diseases, providing knowledge about the peculiarities of orphan drugs.
As established in the Strategic Plan, there are three fundamental axes that, from the Association, are established as priorities to advance in the improvement of public health and our National Health System: access and sustainability, promotion of research and innovation, and competitiveness and sustainability. AELMHU, backed by a long history of work to improve the quality of life of patients with rare diseases and their families, stresses that these three pillars are perfectly aligned with its own objectives and commitments and, therefore, with all the work that, for some time now, has been carried out by the organization.
In the same vein, the organization welcomes the promotion of research and development of advanced therapies and personalized medicine, especially in the context of rare diseases, which are included among the Plan's priorities. Undoubtedly, this commitment to innovation will translate into increased hope for patients with rare diseases.
Therefore, the Association also stresses the importance of fostering a competitive and sustainable environment that will attract investment and strengthen the national pharmaceutical industry, which will directly contribute to improving the availability of innovative treatments for rare pathologies.
"This Strategic Plan represents a new starting point to position Spain as a benchmark in Europe and a recognition by the Government of the pharmaceutical sector as a strategic ally," said Beatriz Perales, president of AELMHU. "It is time to work from collaboration and consensus to ensure that rare disease patients in Spain have access to the greatest possible innovation," she concluded.
With all this, AELMHU reaffirms its commitment to collaborate in the implementation of these measures, offering to collaborate and discuss in order to always ensure the welfare of patients with rare diseases, and stresses that its participation in the Strategic Plan 2024-2028 is a clear sign of its involvement in the transformation of the Spanish pharmaceutical sector towards an innovative, sustainable model that takes into account the particularities of orphan drugs.
